Northwest Biotherapeutics, Inc.

Northwest Biotherapeutics, Inc. is a biotechnology company focused on developing personalized immune therapies for cancer. Its core technology is the DCVax platform, which uses activated dendritic cells to mobilize a patient's own immune system to attack cancer. The company's lead product candidate is DCVax-L, which is in Phase III clinical trials for glioblastoma multiforme (GBM) brain cancer, a highly aggressive form of brain tumor. Additionally, it is developing DCVax-Direct, currently in Phase I trials, for the treatment of inoperable solid tumors. The company's approach aims to harness the body's immune system to target and destroy cancer cells, offering a potential treatment option for patients with limited alternatives.

Northwest Biotherapeutics is listed on the OTC Markets OTCQB exchange under the ticker symbol NWBO. The OTCQB is a U.S. over-the-counter market that provides trading for early-stage and developing companies. The company's stock is traded in U.S. dollars (USD). As an OTC-listed company, it may have different reporting and liquidity requirements compared to major exchanges like the NYSE or Nasdaq. Investors should be aware that OTC stocks can carry higher risks and may have less regulatory oversight.

Northwest Biotherapeutics operates in the Healthcare sector, specifically within the Biotechnology industry. Biotechnology companies use biological processes and living organisms to develop products and therapies, often focusing on areas like genetics, molecular biology, and immunology. In this case, Northwest Biotherapeutics specializes in personalized immune therapies for cancer, leveraging dendritic cell technology. The biotechnology industry is known for high research and development costs, long product development cycles, and significant regulatory hurdles, but also offers the potential for groundbreaking treatments that can address unmet medical needs.

Northwest Biotherapeutics is headquartered in Bethesda, Maryland, United States. The company was founded in 1996, giving it over two decades of experience in the biotechnology field. Its focus on developing personalized immune therapies for cancer places it within the competitive landscape of oncology-focused biotech firms. The company's location in the Washington, D.C. metropolitan area provides access to a skilled workforce and proximity to research institutions. Despite being a relatively small biotech firm, it has advanced its lead product candidate DCVax-L into late-stage clinical trials, reflecting its long-term commitment to developing innovative cancer treatments.

Northwest Biotherapeutics' main product candidates are based on its DCVax platform technology. The lead candidate is DCVax-L, which is in Phase III clinical trials for glioblastoma multiforme (GBM) brain cancer. GBM is the most aggressive form of brain cancer, with limited treatment options and poor prognosis. DCVax-L is a personalized immunotherapy that uses the patient's own dendritic cells to activate an immune response against the tumor. The company is also developing DCVax-Direct, currently in Phase I trials, for inoperable solid tumors. DCVax-Direct is designed to be injected directly into tumors to stimulate a local and systemic immune response. Both candidates represent potential advances in cancer immunotherapy.